<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074009</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000341565</org_study_id>
    <secondary_id>MSKCC-03101</secondary_id>
    <secondary_id>NCI-6003</secondary_id>
    <nct_id>NCT00074009</nct_id>
  </id_info>
  <brief_title>Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma</brief_title>
  <official_title>A Multicenter, Open-Label, Two-Stage, Phase II Study Of PS-341 (LDP-341, NSC # 681239) In Patients With Unresectable Or Metastatic Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary&#xD;
      for their growth.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who&#xD;
      have unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of bortezomib in patients with unresectable or metastatic gastric&#xD;
           or gastroesophageal junction adenocarcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine possible predictors of response to this drug, using pretreatment tumor&#xD;
           immunohistochemistry, in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized, multicenter study.&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every&#xD;
      3 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-33 patients will be accrued for this study within 5-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed unresectable or metastatic gastric or&#xD;
             gastroesophageal junction adenocarcinoma&#xD;
&#xD;
               -  Siewert's class II or III disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion at least 20 mm by conventional&#xD;
                  techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
          -  No history of known or active brain metastases or primary brain tumors&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100% OR&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver&#xD;
             metastases are present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No prior cerebrovascular event&#xD;
&#xD;
          -  No prior orthostatic hypotension&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No peripheral vascular disease requiring surgical management&#xD;
&#xD;
          -  No evidence of acute ischemia or significant conduction abnormality by EKG&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 2 months&#xD;
             after study participation&#xD;
&#xD;
          -  No evidence of peripheral neuropathy&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to bortezomib&#xD;
&#xD;
          -  No other malignancy within the past 3 years except basal cell skin cancer, carcinoma&#xD;
             in situ of the cervix, or adequately treated nonmetastatic prostate cancer&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
          -  No other concurrent uncontrolled illness that would preclude study participation&#xD;
&#xD;
          -  No other medical condition or reason that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 3 weeks since prior immunotherapy&#xD;
&#xD;
          -  No concurrent biological or immunological agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen (including adjuvant chemotherapy)&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agent or therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manish A. Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary K. Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Cancer Center of Queens Hospital</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-3236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, Kelsen DP. A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs. 2011 Dec;29(6):1475-81. doi: 10.1007/s10637-010-9474-7. Epub 2010 Jun 25.</citation>
    <PMID>20574790</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>February 11, 2012</last_update_submitted>
  <last_update_submitted_qc>February 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2012</last_update_posted>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

